MOH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Molina Healthcare Inc. (MOH) is not a good buy for a beginner, long-term investor at this moment. The stock is currently in a bearish trend, with weak technical indicators, negative sentiment from analysts, and poor financial performance in the latest quarter. While the RSI suggests the stock is oversold, the lack of positive catalysts and the challenging industry backdrop make it unsuitable for investment at this time.
The stock is in a bearish trend with the MACD histogram at -8.03 (below 0), RSI at 15.671 (oversold), and bearish moving averages (SMA_200 > SMA_20 > SMA_5). Key support is at 128.587, with resistance at 153.357. The stock is trading below its pivot point, indicating further downside potential.
NULL identified. The RSI indicates the stock is oversold, which may attract short-term traders, but this is not a strong long-term catalyst.
Weak Q4 2025 financial performance with a net income loss of $160 million and a 170.95% YoY drop in EPS.
Analysts have significantly lowered price targets, citing poor earnings and challenging industry conditions.
Negative news sentiment, including a 29% stock drop after Q4 results and weak 2026 guidance.
Bearish technical indicators and lack of significant trading activity from hedge funds or insiders.
In Q4 2025, revenue increased by 8.34% YoY to $11.375 billion, but net income dropped to -$160 million (-163.75% YoY), and EPS fell to -3.15 (-170.95% YoY). Gross margin also declined by 23.79% YoY to 10.51%. These metrics indicate significant financial challenges.
Analysts have broadly downgraded their price targets and maintain neutral or underweight ratings. Recent price target reductions include Goldman Sachs ($124), Deutsche Bank ($109), Barclays ($133), and others. The consensus reflects skepticism about the company's ability to recover in the near term, given its exposure to cyclical and low-margin government contracts.
